基于ePRO的癌症患者症状管理的有效性:随机对照研究的系统审查和元分析
Lin Hang1,2, Jieping Zhang3,4, Zhongjie Lu2
1Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
概括
基于电子患者报告结果 (ePRO) 的症状管理显示了改善癌症患者生活质量的前景. 然而,由于结果不稳定,其对再接收率,症状负担和死亡率的影响需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 数字健康数字健康
- 基于证据的医学基于证据的医学.
背景情况:
- 癌症患者经历了影响其福祉的各种症状.
- 有效的症状管理对于改善患者的治疗结果和生活质量至关重要.
- 电子患者报告结果 (ePROs) 提供了一种新的方法来远程监测和管理症状.
研究的目的:
- 系统地综合关于基于ePRO的成年癌症患者症状管理有效性的证据.
- 评估对再接收率,生活质量,症状负担,焦虑,抑郁和死亡率的影响.
主要方法:
- 2018年1月至2023年5月期间发表的随机对照试验 (RCT) 的系统审查和元分析.
- 在主要数据库 (PubMed,科学网,EMBASE,科克兰图书馆,CINAHL,Scopus) 进行的搜索.
- 使用Cochrane偏差风险工具版本2进行偏差风险评估;执行子组和灵敏度分析.
主要成果:
- 基于ePRO的症状管理显著改善了生活质量 (QOL) (SMD=4.42,P=0.04).
- 对于再入院率,症状负担,焦虑,抑郁或总体死亡率没有发现显著差异.
- 小组分析表明30天内再入院率较低 (RR = 0.85,P = 0.03) 和1个月内QOL改善 (SMD = 4.35,P < 0.00001).
- 敏感性分析显示,再接收率和QOL的结果不稳定,这表明需要进一步研究.
结论:
- 基于ePRO的症状管理表明,它对癌症患者的生活质量产生了积极的影响.
- 长期影响和对重收等关键结果的整体影响需要进一步验证,因为研究有限和发现不稳定.
- 癌症护理中的症状管理仍然是持续研究和技术整合的重要领域.
相关概念视频
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:12Hazard Ratio
90
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
90
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K